Latest Bavarian Nordic A/S Stories
KVISTGARD, Denmark, February 1, 2011 /PRNewswire-FirstCall/ -- Bavarian Nordic A/S (NASDAQ OMX: BAVA) announced today that it has completed a clinical Phase 2 trial of its smallpox vaccine, IMVAMUNE(R), in individuals suffering from atopic dermatitis (a.k.a. eczema).
Smallpox Vaccine Represents the Company's First Major U.S. Product Sale KVISTGARD, Denmark, July 13 /PRNewswire/ -- Bavarian Nordic A/S (Nasdaq OMX: BAVA) announced today that it has delivered 1 million doses of its smallpox vaccine IMVAMUNEÂ® to the U.S.
KVISTGARD, Denmark, November 30 /PRNewswire-FirstCall/ -- Bavarian Nordic A/S (OMX: BAVA) announced today that the company expects to file a New Drug Submission (NDS) for its third-generation smallpox vaccine, IMVAMUNE(R) with the Canadian Authorities, Health Canada in 2010.
KVISTGARD, Denmark, November 17 /PRNewswire-FirstCall/ -- Bavarian Nordic A/S (OMX: BAVA) announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million. The contract provides funds to validate the new freeze-dried manufacturing process and the associated pre-clinical and clinical studies to...
KVISTGARD, Denmark, November 11 /PRNewswire-FirstCall/ -- Today Bavarian Nordic published the company's third quarterly report 2009.
- An imitative word; an onomatopoetic word.